New gene patent suit sparks talk of trolls

A month after a unanimous U.S. Supreme Court struck down seven Myriad Genetics patents tied to two breast cancer susceptibility genes, the company has touched off another legal knock-down-drag-out to enforce other intellectual property unaffected by the decision—with consequences likely to include a new wave of patent-assertion litigation across the industry.

Earlier this month, Myriad sued two rivals in U.S. District Court, Utah District, claiming they infringed 10 patents associated with BRCA1 and BRCA2 that were not covered by the Supreme Court’s June 13 ruling.

Does Myriad’s latest lawsuit indeed mean that patent trolling has come to biopharma?

Read the full article here: New Gene Patent Suit Sparks Talk of Trolls

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: The evolutionary history of the COVID-19 coronavirus

Infographic: The evolutionary history of the COVID-19 coronavirus

Reuters analysed over 185,000 genome samples from the Global Initiative on Sharing All influenza Data (GISAID), the largest database of ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend